Emcure Pharmaceuticals Limited (NSE:EMCURE)
India · Delayed Price · Currency is INR | Market Cap | 311.50B +49.6% |
| Revenue (ttm) | 92.16B +16.7% |
| Net Income | 9.24B +35.7% |
| EPS | 48.77 +33.9% |
| Shares Out | 189.59M |
| PE Ratio | 33.69 |
| Forward PE | 27.22 |
| Dividend | 3.00 (0.18%) |
| Ex-Dividend Date | n/a |
| Volume | 286,251 |
| Average Volume | 384,832 |
| Open | 1,644.00 |
| Previous Close | 1,643.00 |
| Day's Range | 1,636.10 - 1,704.30 |
| 52-Week Range | 1,013.40 - 1,830.00 |
| Beta | n/a |
| RSI | 54.42 |
| Earnings Date | May 5, 2026 |
About Emcure Pharmaceuticals
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the develop... [Read more]
Financial Performance
In fiscal year 2026, Emcure Pharmaceuticals's revenue was 92.16 billion, an increase of 16.72% compared to the previous year's 78.96 billion. Earnings were 9.24 billion, an increase of 35.67%.
Financial StatementsNews
Emcure Pharmaceuticals Transcript: Q4 25/26
FY 2026 saw 16.6% revenue growth, 41% adjusted PAT growth, and margin expansion, driven by strong international and resilient domestic performance. FY 2027 guidance is for low-to-mid-teen revenue growth and further margin gains, with Zuventus integration stabilizing.
Emcure Pharmaceuticals Transcript: Q3 25/26
Q3 FY26 saw 20.4% revenue growth and 48% PAT increase, driven by strong domestic and international performance, strategic in-licensing, and new launches like semaglutide. EBITDA margin improved to 19.5%, with a positive outlook for sustained growth and margin expansion.
Emcure Pharmaceuticals Transcript: Q2 25/26
Q2 FY2026 saw 13% revenue growth and record profits, driven by strong domestic and international performance. Strategic moves included a Novo Nordisk partnership for Semaglutide and full Zuventus acquisition, with margin and debt targets updated following recent M&A.
Emcure Pharmaceuticals Transcript: Q1 25/26
Q1 FY2026 delivered strong growth with revenue up 15.7% and profit after tax up 41% year-over-year. Domestic and international segments both outperformed, with new product launches and partnerships driving momentum. EBITDA margin improved to 19.2%.
Emcure Pharmaceuticals Transcript: Q4 24/25
FY 2025 saw 19% revenue growth and 34% PAT increase, driven by strong domestic and international performance, portfolio expansion, and successful integration of acquisitions. FY 2026 guidance targets 13-14% revenue growth, 150 bps margin improvement, and further debt reduction.
Emcure Pharmaceuticals Transcript: Q3 24/25
Q3 FY25 saw 18% revenue growth and 36% adjusted PAT growth, led by strong international and domestic performance. Margins are expected to improve over the next few years, with new launches in derma and ophthalmology, and a focus on vertical integration for semaglutide.